Status:
COMPLETED
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.
Eligibility Criteria
Inclusion
- Participants must have an ECOG performance status of less than or equal to 1
- Participants must have had prior therapy;Participants who have received adjuvant or neoadjuvant anti-PD(L)1 therapy andprogressed within 6 months of completing therapy will be considered IO refractory.
- Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1
Exclusion
- Participants with suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
- Participants with carcinomatous meningitis
- Participants with other active malignancy requiring concurrent intervention
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
May 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 25 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03335540
Start Date
May 7 2018
End Date
August 25 2021
Last Update
September 26 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Chicago, Illinois, United States, 60637
2
University of Chicago
Chicago, Illinois, United States, 60637
3
Local Institution - 0002
Baltimore, Maryland, United States, 21287
4
Local Institution - 0003
Pittsburgh, Pennsylvania, United States, 15232